Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Bioventures 2014 L.P. Mpm Sells 59,277 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 59,277 shares of the company’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $0.89, for a total value of $52,756.53. Following the sale, the insider directly owned 4,924,566 shares of the company’s stock, valued at approximately $4,382,863.74. This represents a 1.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Thursday, December 4th, Bioventures 2014 L.P. Mpm sold 83,230 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $80,733.10.
• On Wednesday, December 3rd, Bioventures 2014 L.P. Mpm sold 57,225 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total value of $49,785.75.
• On Monday, December 1st, Bioventures 2014 L.P. Mpm sold 60,917 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $57,261.98.
• On Friday, November 28th, Bioventures 2014 L.P. Mpm sold 20,277 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total transaction of $20,074.23.
• On Wednesday, November 26th, Bioventures 2014 L.P. Mpm sold 60,733 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $59,518.34.
• On Tuesday, November 25th, Bioventures 2014 L.P. Mpm sold 42,533 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.92, for a total transaction of $39,130.36.
• On Monday, November 24th, Bioventures 2014 L.P. Mpm sold 88,802 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $87,025.96.
• On Friday, November 21st, Bioventures 2014 L.P. Mpm sold 64,331 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.83, for a total transaction of $53,394.73.
• On Thursday, November 20th, Bioventures 2014 L.P. Mpm sold 41,152 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total transaction of $36,625.28.
• On Wednesday, November 19th, Bioventures 2014 L.P. Mpm sold 66,324 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $62,344.56.

Werewolf Therapeutics Stock Down 1.4%

Shares of HOWL traded down $0.01 during mid-day trading on Friday, reaching $0.98. The company’s stock had a trading volume of 67,889 shares, compared to its average volume of 502,483. The company has a market cap of $47.67 million, a price-to-earnings ratio of -0.61 and a beta of 0.74. The business has a fifty day moving average of $1.40 and a 200 day moving average of $1.33. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 1 year low of $0.60 and a 1 year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. As a group, analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Large investors have recently made changes to their positions in the stock. MPM Asset Management LLC raised its stake in shares of Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after acquiring an additional 25,688 shares in the last quarter. MPM Bioimpact LLC boosted its position in Werewolf Therapeutics by 0.9% during the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after purchasing an additional 20,799 shares during the period. Bank of America Corp DE grew its holdings in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares during the last quarter. Vanguard Group Inc. grew its holdings in Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $409,000. Institutional investors own 64.84% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. JMP Securities reduced their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Bank of America dropped their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Finally, Zacks Research downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Werewolf Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $7.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.